Lv2
160 积分 2022-09-19 加入
Cancer burden and control in China: landscape, trends and challenges
3天前
已完结
Trends in Ophthalmology Practice Consolidation: 2015–2022
1个月前
已关闭
中国葡萄膜炎临床诊断要点专家共识（2025年）
1个月前
已完结
中国眼内糖皮质激素植入剂治疗非感染性葡萄膜炎专家共识（2026年）
1个月前
已完结
Sialylated CD43 forms a glyco-immune barrier that restrains antileukemic immunity
2个月前
已完结
《中国卒中中心报告2022》概要
3个月前
已关闭
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
5个月前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
5个月前
已完结
Efficacy and Safety of Spleen Tyrosine Kinase and VEGFR-2 Dual-Target Kinase Inhibitor (OT202) in Dry Eye: A Randomized, Vehicle-Controlled Phase 2 Trial
5个月前
已完结
An Unusual Cause of Hypolipidemia With Cirrhosis in a Father-Son Pair
5个月前
已完结
皖公网安备34019202002308
